Lower Abdominal Distress in 2 Patients: What Next?

Slideshow

Both patients complain of diarrhea x1 year; neither presents with weight loss, melena, or hematochezia. What test, which treatment would you choose?

Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!
Recent Videos
Related Content
FIT Tests, Direct Mailed, Increase Initiation of CRC Screening in Adults Aged 45 to 49 / image credit University of Southern California, Artin Galoosian, MD, MA

FIT Tests, Direct Mailed, Increase Initiation of CRC Screening in Adults Aged 45 to 49

Grace Halsey
September 4th 2025
Article
Site Logo

Clostridium difficile: New Guidelines Confront Hypervirulent Strain

Christina M. Surawicz, MD
September 4th 2025
Podcast
Real-World Study Confirms Upadacitinib’s Efficacy in Crohn Disease Treatment: Daily Dose / image credit: ©New Africa/AdobeStock

Real-World Study Confirms Upadacitinib’s Efficacy in Crohn Disease Treatment: Daily Dose

Sydney Jennings
September 4th 2025
Article
Clinical Tips for Using Antibiotics and Corticosteroids in IBD

Clinical Tips for Using Antibiotics and Corticosteroids in IBD

Raymond Cross, MD
September 4th 2025
Podcast
Upadacitinib Found Effective in Achieving Remission in Crohn Disease, Including Biologic-Experienced Patients

Upadacitinib Found Effective in Achieving Remission in Crohn Disease, Including Biologic-Experienced Patients

Sydney Jennings
September 4th 2025
Article
Guselkumab (Tremfya) Gains FDA Approval for Crohn Disease: Daily Dose / image credit: ©New Africa/AdobeStock

Guselkumab (Tremfya) Gains FDA Approval for Crohn Disease: Daily Dose

Sydney Jennings
September 4th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.